Inhibition of SRF/myocardin reduces aortic stiffness by targeting vascular smooth muscle cell stiffening in hypertension

Conclusions
SRF/myocardin pathway acts as a pivotal mediator of aortic VSMC mechanical properties and plays a central role in the pathological aortic stiffening in hypertension. Attenuation of aortic VSMC stiffening by pharmacological inhibition of SRF/myocardin signalling presents a novel therapeutic strategy for the treatment of hypertension by targeting the cellular contributors to aortic stiffness.

Source: Cardiovascular Research - January 22, 2017 Category: Cardiology Authors: Zhou, N., Lee, J.-J., Stoll, S., Ma, B., Wiener, R., Wang, C., Costa, K. D., Qiu, H. Tags: Vascular biology Source Type: research